Reverse Transcriptase Inhibitors in AGS

Aicardi-Goutières Syndrome (AGS) Clinical Trial

— RTIs in AGS  

Official title:

A Pilot Clinical Trial of Reverse Transcriptase Inhibitors in Children With Aicardi-Goutières Syndrome (AGS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02363452
• Other study ID #: P140203
• Status: Completed
• Phase: Phase 2
• Start date: September 10, 2015
• Est. completion date: June 2018

Study information

• Verified date: February 2019
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine if treatment with reverse transcriptase inhibitors returns the interferon signature observed in patients with AGS to normal levels.

Description:

AGS is a genetically heterogeneous disease resulting from mutations in any one of the genes encoding the 3-prime repair exonuclease TREX1 (AGS1), the three non-allelic components of the RNASEH2 endonuclease complex (AGS2, 3 and 4), the Sam domain and HD domain containing protein (SAMHD1; AGS5) which functions as a deoxynucleoside triphosphate triphosphohydrolase, the double stranded RNA editing enzyme ADAR1, or the cytosolic dsRNA sensor IFIH1. It is hypothesized that AGS1-6 are involved in limiting the accumulation of intracellular nucleic acid species, a failure of which process results in triggering of an innate immune response that is more normally induced by viral nucleic acids. That is, in the absence of AGS-related protein activity, endogenous nucleic acids accumulate and are sensed as viral or 'non-self', leading to the induction of an interferon (IFN) alpha mediated immune response and the production of antibodies against self nucleic acids. AGS is associated with increased levels of interferon alpha in the cerebrospinal fluid (CSF) and serum. Available data suggest that AGS might be treated with (particular) reverse transcriptase inhibitors (which compounds can potentially disrupt both exogenous retroviral and endogenous retroelement cycling). No systematic approach to treatment in AGS has been explored. The investigators hypothesis is that reverse transcriptase inhibitors will also inhibit the reverse transcription of endogenous retroelements which are deemed to be responsible for initiating the tissue damage seen in AGS. Consequently, for the purpose of the investigators pilot study, it would be ideal to assess the effects of therapy by monitoring a reactive biomarker.

This is a single centre, open, single arm, phase II study in children with AGS. This study design is justified because no data are available about antiretroviral drug efficacy in children with AGS. Moreover, this study is the first step before a phase III study of drug efficacy.

The investigators propose a pilot clinical trial of selected reverse transcriptase inhibitors in AGS patients, with the specific endpoint of assessing the effect of treatment on the disease-associated interferon signature. The investigators propose to evaluate the safety of combination therapy comprising the three nucleoside analog reverse-transcriptase inhibitors (NRTIs) zidovudine (AZT), lamivudine (3TC), abacavir (ABC) in patients with AGS over a 52 week period of treatment. The inclusion period is 12 months. Patients can not participate in a biomedical trial of another drug during the 18 month follow-up (12 months of treatment period plus 6 months post treatment period).

A total of six visits (including a final visit) are scheduled for this trial over a period of 18 months (M1, M3, M6, M9, M12, M18) for all patients.

Drugs will be dispensed for medication at home, at usual doses recommended in HIV infection. Subjects will be dosed according to French guidelines. Dosing will be reviewed at each study visit against current weight, and modified as necessary in accordance with French dosing guidelines.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 11
• Est. completion date: June 2018
• Est. primary completion date: January 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Month to 17 Years

Eligibility

Inclusion Criteria:

• A molecular diagnosis of AGS i.e. biallelic or known dominant mutations, with pathogenicity assessed using our extensive mutation database / functional data, in any of TREX1, RNASEH2A, RNASEH2B, RNASEH2C and SAMHD1 genes

• A pre-defined interferon signature (consistently present, moderate or high, on at least three occasions, over a period of 6 months prior to enrolment in the study)

• Age = 1 month and < 18 years (either sex)

• Patient beneficiary or affiliated to " health insurance"

• Written informed consent

Exclusion Criteria:

• Pre-existing disease, not due to AGS, which would preclude the use of zidovudine, Lamivudine and abacavir (as currently assessed in routine clinical HIV-related practice)

• HLA B57-01 positive result, which indicates a greater risk of abacavir hypersensitivity reaction

• Patients with abnormally low neutrophile counts (<0.75 x 109/l), or abnormally low haemoglobin levels (<7.5 g/dl or 4.65 mmol/l)(zidovudine contraindication)

• Positive serology for HIV, HBV

• Known history of cirrhosis and history of clinically relevant hepatitis within last 6 months

• Moderate to severe renal impairment

• Pregnancy, breastfeeding

• Patient participating to a biomedical research with drug

Related Conditions & MeSH terms

• Aicardi-Goutières Syndrome (AGS)
• Autoimmune Diseases of the Nervous System
• Nervous System Malformations
• Syndrome

Intervention

Drug:
• Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir
Oral Solution (syrup) or Tablets

Locations

Country	Name	City	State
France	Hôpital Necker - Enfants Malades	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris

Country where clinical trial is conducted

France, 

References & Publications (2)

Crow YJ, Vanderver A, Orcesi S, Kuijpers TW, Rice GI. Therapies in Aicardi-Goutières syndrome. Clin Exp Immunol. 2014 Jan;175(1):1-8. doi: 10.1111/cei.12115. Review. — View Citation

Rice GI, Meyzer C, Bouazza N, Hully M, Boddaert N, Semeraro M, Zeef LAH, Rozenberg F, Bondet V, Duffy D, Llibre A, Baek J, Sambe MN, Henry E, Jolaine V, Barnerias C, Barth M, Belot A, Cances C, Debray FG, Doummar D, Frémond ML, Kitabayashi N, Lepelley A, — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Interferon signature	Interferon Score	Before and after 12 months of treatment
Secondary	Interferon signature	Interferon Score	Month 18
Secondary	Adverse Events		Baseline until Month 18
Secondary	Interferon Activity Level in cerebrospinal fluid (UI/L)		Within the 12 month on treatment
Secondary	Interferon Activity Level in blood (UI/L)		Within the 12 month on treatment
Secondary	Interferon Activity Level in blood (UI/L)		month 18
Secondary	Interferon Protein in cerebrospinal fluid (Fg/mL)		within the 12 month on treatment
Secondary	Interferon Protein in blood (FG/mL)		Within the 12 month on treatment
Secondary	Interferon Protein in blood (Fg/mL)		Month 18
Secondary	Neurological assessment	Scale for Evaluation of Movement Disorders Vineland Adaptive Behaviour Scales	Baseline
Secondary	Neurological assessment	Scale for Evaluation of Movement Disorders Vineland Adaptive Behaviour Scales	Month 12
Secondary	Neurological assessment	Scale for Evaluation of Movement Disorders Vineland Adaptive Behaviour Scales	Month 18
Secondary	Radiological assessment	MRI, CT Scan	Baseline
Secondary	Radiological assessment	MRI, CT Scan	Month 12
Secondary	dosages of abacavir	Blood sample	Month 1
Secondary	dosages of zidovudine	Blood sample	Month 1
Secondary	dosages of lamivudine	Blood sample	Month 1
Secondary	dosages of zidovudine	Blood sample	Month 3
Secondary	dosages of lamivudine	Blood sample	Month 3
Secondary	dosages of abacavir	Blood sample	Month 3
Secondary	dosages of abacavir	Blood sample	Month 6
Secondary	dosages of zidovudine	Blood sample	Month 6
Secondary	dosages of lamivudine	Blood sample	Month 6
Secondary	Number of chilblains lesions		baseline
Secondary	Number of chilblains lesions		Month 1
Secondary	Number of chilblains lesions		Month 3
Secondary	Number of chilblains lesions		Month 6
Secondary	Number of chilblains lesions		Month 9
Secondary	Number of chilblains lesions		Month 12
Secondary	Number of chilblains lesions		Month 18